Terms: = Kidney tumors AND RNF43, DKFZp781H02126, 54894, Q68DV7, URCC, RNF124, MGC125630, FLJ20315, DKFZp781H0392
12 results:
1. Pan-cancer analysis identifies rnf43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract] [Full Text] [Related]
2. rnf43 is a novel tumor-suppressor and prognostic indicator in clear cell renal cell carcinoma.
Zhu D; Zhang L; Shi X; Gao S; Yue C; Zhang L; Bai YU; Wang Q; Okada A; Yasui T; Wang C; Cui X; Zuo LI
Oncol Res; 2021; 29(3):159-174. PubMed ID: 37304674
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive Genomic Profiling of NF2-Mutated kidney tumors Reveals Potential Targets for Therapy.
Hacking SM; Pavlick D; Wang Y; Carneiro BA; Mullally M; Lu S; Canepa M; Bratslavsky G; Jacob J; Necchi A; Spiess PE; Wang L; Yakirevich E; Ross J
Oncologist; 2023 Jul; 28(7):e508-e519. PubMed ID: 36917021
[TBL] [Abstract] [Full Text] [Related]
4. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract] [Full Text] [Related]
5. Combining expression of rnf43 and infiltration level of CD163
Zhu D; Shi X; Tian Y; Li H; Tang B; Zhang Z; Zhang Z; Zuo L
Cancer Med; 2023 Feb; 12(4):3962-3971. PubMed ID: 36097369
[TBL] [Abstract] [Full Text] [Related]
6. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Feldman DR; Ged Y; Lee CH; Knezevic A; Molina AM; Chen YB; Chaim J; Coskey DT; Murray S; Tickoo SK; Reuter VE; Patil S; Xiao H; Aghalar J; Apollo AJ; Carlo MI; Motzer RJ; Voss MH
Cancer; 2020 Dec; 126(24):5247-5255. PubMed ID: 32975815
[TBL] [Abstract] [Full Text] [Related]
7. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.
Chen YB; Xu J; Skanderup AJ; Dong Y; Brannon AR; Wang L; Won HH; Wang PI; Nanjangud GJ; Jungbluth AA; Li W; Ojeda V; Hakimi AA; Voss MH; Schultz N; Motzer RJ; Russo P; Cheng EH; Giancotti FG; Lee W; Berger MF; Tickoo SK; Reuter VE; Hsieh JJ
Nat Commun; 2016 Oct; 7():13131. PubMed ID: 27713405
[TBL] [Abstract] [Full Text] [Related]
8. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
Voss MH; Molina AM; Chen YB; Woo KM; Chaim JL; Coskey DT; Redzematovic A; Wang P; Lee W; Selcuklu SD; Lee CH; Berger MF; Tickoo SK; Reuter VE; Patil S; Hsieh JJ; Motzer RJ; Feldman DR
J Clin Oncol; 2016 Nov; 34(32):3846-3853. PubMed ID: 27601542
[TBL] [Abstract] [Full Text] [Related]
9. Unclassified renal cell carcinoma: a clinicopathological, comparative genomic hybridization, and whole-genome exon sequencing study.
Hu ZY; Pang LJ; Qi Y; Kang XL; Hu JM; Wang L; Liu KP; Ren Y; Cui M; Song LL; Li HA; Zou H; Li F
Int J Clin Exp Pathol; 2014; 7(7):3865-75. PubMed ID: 25120763
[TBL] [Abstract] [Full Text] [Related]
10. Unclassified renal cell carcinoma: impact on survival following nephrectomy.
Crispen PL; Tabidian MR; Allmer C; Lohse CM; Breau RH; Blute ML; Cheville JC; Leibovich BC
Urology; 2010 Sep; 76(3):580-6. PubMed ID: 20223503
[TBL] [Abstract] [Full Text] [Related]
11. Unclassified renal cell carcinoma: an analysis of 85 cases.
Karakiewicz PI; Hutterer GC; Trinh QD; Pantuck AJ; Klatte T; Lam JS; Guille F; de La Taille A; Novara G; Tostain J; Cindolo L; Ficarra V; Schips L; Zigeuner R; Mulders PF; Chautard D; Lechevallier E; Valeri A; Descotes JL; Lang H; Soulie M; Ferriere JM; Pfister C; Mejean A; Belldegrun AS; Patard JJ
BJU Int; 2007 Oct; 100(4):802-8. PubMed ID: 17822461
[TBL] [Abstract] [Full Text] [Related]
12. A novel oncoprotein rnf43 functions in an autocrine manner in colorectal cancer.
Yagyu R; Furukawa Y; Lin YM; Shimokawa T; Yamamura T; Nakamura Y
Int J Oncol; 2004 Nov; 25(5):1343-8. PubMed ID: 15492824
[TBL] [Abstract] [Full Text] [Related]
